Duavee Manufacturer Copay Program: Every Way to Lower Your Cost in 2026

What Is Duavee and Who Is It For?

Duavee is the only FDA-approved tissue selective estrogen complex (TSEC), pairing conjugated estrogens (CE) 0.45 mg with bazedoxifene (BZA) 20 mg in a single daily tablet. The bazedoxifene component acts as a selective estrogen receptor modulator (SERM) in uterine tissue, protecting the endometrium so no separate progestogen is needed.

Which women are candidates?

Duavee is approved for two indications: moderate-to-severe vasomotor symptoms (hot flashes, night sweats) in postmenopausal women, and prevention of postmenopausal osteoporosis. Because it contains estrogen, it is indicated only for women who have a uterus. Women who have had a hysterectomy have other, often less expensive, estrogen-only options.

The SMART-1 through SMART-5 trial program demonstrated that CE/BZA significantly reduced the frequency and severity of moderate-to-severe hot flashes versus placebo, with endometrial protection equivalent to CE plus a progestogen.

Life-stage framing

Most women who are offered Duavee are in one of two groups: early postmenopause (last menstrual period within the past ten years or under age 60), where the cardiovascular benefit-risk ratio is most favorable according to The Menopause Society's 2023 Position Statement on Hormone Therapy, or perimenopausal women with breakthrough bleeding patterns that make progestogen-containing regimens complicated.

How Much Does Duavee Cost Without Insurance?

The average cash price for a 30-day supply of Duavee sits at approximately $240, though pharmacy-by-pharmacy variation is wide. Specialty and independent pharmacies may price it differently from large chains.

Why the cost is high

Duavee has no FDA-approved generic as of early 2026. Bazedoxifene is not separately available in the United States, so standard compounding pharmacies cannot easily replicate the fixed-dose combination. Compounded alternatives that attempt to approximate this combination vary widely in quality and are not bioequivalent to the branded tablet.

The compounding alternative

Some compounding pharmacies offer bazedoxifene combined with estradiol or conjugated estrogens at costs that can approach $0 with certain discount programs, though quality and dosing consistency are not FDA-validated. The FDA has issued guidance cautioning that compounded drugs lack the safety, efficacy, and manufacturing oversight of approved medications. Discuss the trade-offs openly with your prescriber before substituting a compounded version.

Pfizer's Manufacturer Copay Savings Program

Pfizer operates a copay savings card for Duavee that, when active and when you meet eligibility criteria, can reduce your out-of-pocket cost per fill. The program structure Pfizer has historically used works like this:

Who qualifies

• You have commercial (private) insurance that covers Duavee, even partially.
• You are a resident of the United States or Puerto Rico.
• You are NOT enrolled in a federal or state government insurance program, including Medicare, Medicaid, TRICARE, or any state pharmaceutical assistance program. Government program patients are explicitly excluded from manufacturer copay cards under federal anti-kickback rules.
• You fill at a participating retail or specialty pharmacy.

What the savings card typically covers

Pfizer's programs have historically offered to cover the gap between your insurance copay and a stated out-of-pocket cap, sometimes as low as $0-$35 per fill, up to an annual maximum benefit (often $3,000-$5,000 per year). The exact amounts are set by Pfizer and change without notice.

These figures are illustrative of the program structure, not a current guarantee. Programs change frequently, new limits are set at the start of each calendar year, and Pfizer may modify or discontinue the card at any time.

How to activate the card

1. Go to Pfizer's official savings portal (search "Duavee savings card pfizer.com" or ask your pharmacist for the current enrollment URL, as landing pages shift).
2. Register with your name, date of birth, insurance information, and prescriber's NPI.
3. Print or download the card, or request a physical card.
4. Present it at the pharmacy every time you fill, alongside your insurance card.
5. Re-verify eligibility each January, because annual resets are common.

What to do if the card is rejected at the pharmacy

Pharmacy benefit managers sometimes block copay card assistance through a mechanism called "copay accumulator" or "copay maximizer" programs. If this happens, ask your pharmacy to run the Pfizer card as a secondary payer. If that fails, contact Pfizer's patient support line directly (the number is printed on the card or available on pfizer.com) and ask for a manual override or alternative assistance pathway.

Insurance Coverage: What to Expect and How to Fight a Denial

Insurance coverage for Duavee is inconsistent. Some commercial plans place it on a preferred tier; others require step therapy (trying and failing a less expensive estrogen first) or prior authorization.

Prior authorization and step therapy

Many plans require documented proof that you have tried and failed at least one lower-tier HRT option, such as oral conjugated estrogens alone plus a progestogen, or a low-dose estradiol patch. If your prescriber believes Duavee is clinically necessary because of poor progestogen tolerance, breakthrough bleeding, or safety concerns, that rationale should be clearly documented in the prior authorization letter.

ACOG's guidance on menopausal hormone therapy supports individualized prescribing based on symptom burden, bleeding history, and patient preference, which is exactly the language a prior authorization appeal should use.

Step therapy override laws

As of 2026, more than 30 states have enacted step therapy override laws that require insurers to grant an exception when a prescriber certifies that the required first-step drug is contraindicated, has been tried and failed, or would cause harm. Ask your prescriber's office to check your state's law and file an override request if applicable.

Formulary exceptions

If Duavee is not on your plan's formulary at all, you can request a formulary exception. Your prescriber submits a letter explaining medical necessity. Success rates vary, but a well-documented letter citing the SMART trial data and your specific clinical situation (e.g., progestogen intolerance confirmed by prior adverse reaction) meaningfully improves the odds.

Other Ways to Reduce What You Pay for Duavee

GoodRx and third-party discount cards

GoodRx, RxSaver, and similar services aggregate pharmacy discount prices. For Duavee, these prices at major chains can sometimes be lower than the cash price, though they are rarely as low as the manufacturer copay card for insured patients. Compare prices across at least three pharmacies before filling.

NeedyMeds and patient assistance

NeedyMeds (needymeds.org is not on our allow-list, so confirm this independently) catalogues manufacturer patient assistance programs (PAPs). Pfizer's PAP, called Pfizer RxPathways, may provide Duavee at reduced or no cost for uninsured or underinsured women who meet income thresholds, typically below 400% of the federal poverty level. Contact Pfizer RxPathways directly at the number on pfizer.com.

Pharmacy price shopping

A 2019 JAMA study found that prices for the same drug varied by more than 10-fold across pharmacies in the same geographic market. Call three or four pharmacies, give them the NDC number for Duavee (ask your prescriber's office), and compare cash prices before committing to one pharmacy.

Splitting the fill or adjusting supply

Some plans charge a lower per-unit copay for a 90-day supply versus three separate 30-day fills. If your plan allows mail-order pharmacy, that channel sometimes carries a lower cost share.

Pregnancy, Lactation, and Contraception: Required Reading

Duavee is contraindicated in pregnancy. This is a non-negotiable safety point that must be understood before starting this medication.

Pregnancy

Conjugated estrogens combined with bazedoxifene is FDA Pregnancy Category X. Animal data show fetal harm, and there is no clinical scenario in which the benefits to a pregnant woman outweigh the risks. If you are pregnant or suspect you might be pregnant, do not start Duavee, and contact your clinician immediately if you become pregnant while taking it.

The Menopause Society's 2023 position statement notes that hormone therapy is designed for postmenopausal women and is not appropriate for women who are premenopausal except in specific clinical contexts such as premature ovarian insufficiency, and even then, pregnancy status must be confirmed as negative before initiation.

Perimenopausal women: contraception is essential

Women in perimenopause can still ovulate, even when cycles are irregular. A 2018 review in Menopause confirmed that women over 40 with irregular cycles remain at meaningful risk of unintended pregnancy and require contraception until 12 consecutive months of amenorrhea (in women over 50) or 24 consecutive months (in women under 50).

Duavee itself provides no contraceptive protection. If you are perimenopausal and your clinician prescribes Duavee for vasomotor symptom control, you need a separate, reliable contraceptive method. Non-hormonal options (copper IUD, barrier methods) are preferred because adding additional systemic hormones requires careful benefit-risk assessment.

Lactation

Duavee is not indicated for use during lactation. Conjugated estrogens can suppress milk production, and estrogen transfer into breast milk is documented. Bazedoxifene transfer into human milk has not been adequately studied. Because Duavee is a postmenopausal therapy, its use during lactation is essentially a non-scenario clinically, but if a woman in early postpartum (before natural menopause) were prescribed it off-label, breastfeeding should be discontinued.

Women with premature ovarian insufficiency (POI)

Women under 40 with POI sometimes receive HRT for cardioprotection and bone preservation. Duavee has not been studied in this population. Most guidelines, including ACOG Practice Bulletin 2022, recommend standard estrogen-progestogen regimens rather than TSECs for this younger age group, partly because POI patients often want to preserve fertility options and need clear guidance that HRT does not restore fertility.

Who Duavee Is Right For (and Who Should Consider Something Else)

A good fit

• Postmenopausal women with a uterus who have troublesome vasomotor symptoms and who have had difficulty tolerating progestogen side effects (mood changes, bloating, bleeding).
• Women who prefer a single tablet over separate estrogen plus progestogen pills or patches.
• Women at or near the threshold for osteoporosis prevention who want symptom relief and skeletal protection from one medication.
• Women who have commercially insured plans where the Pfizer savings card can make the cost manageable.

A less ideal fit

• Women without a uterus: estrogen-only therapy is simpler and typically less expensive.
• Women on Medicare or Medicaid: the manufacturer copay card is off-limits, and the high cash price without assistance is a significant barrier.
• Women in perimenopause who are still having regular cycles: ovulation is still occurring, pregnancy risk is real, and adding estrogen without confirmed postmenopausal status requires careful clinical judgment.
• Women with a history of estrogen-sensitive breast cancer: the prescribing information lists known or suspected estrogen-dependent neoplasia as a contraindication.
• Women with active or recent venous thromboembolism (VTE): oral estrogens carry a higher VTE risk than transdermal formulations, and Duavee is an oral product.

PCOS, Bone Health, and Other Female-Specific Considerations

PCOS

Women with PCOS often have anovulatory cycles and may reach menopause with a different hormonal trajectory. There are no PCOS-specific trials for CE/BZA. Because PCOS does not accelerate menopause, women with PCOS who are postmenopausal can be evaluated for Duavee on standard postmenopausal criteria.

Bone health

The SMART-5 trial showed that CE 0.45 mg/BZA 20 mg maintained or improved lumbar spine and femoral neck bone mineral density compared with placebo at 12 months, with effects comparable to CE 0.45 mg plus medroxyprogesterone acetate. If your prescriber is weighing Duavee partly for bone preservation, this trial-level evidence supports that use, provided you meet the general postmenopausal osteoporosis prevention criteria.

The National Osteoporosis Foundation (not on our allow-list) and ACOG both recommend a discussion of non-pharmacological bone health strategies alongside any HRT. Weight-bearing exercise and adequate calcium (1,000-1,200 mg/day from food and supplements combined, depending on age) and vitamin D (600-800 IU/day minimum, higher if deficient) remain the backbone of any bone preservation plan.

Cardiovascular considerations

Oral estrogen, including CE, is associated with a modest increase in VTE risk compared with transdermal estradiol. A 2019 BMJ study by Vinogradova et al. found that oral estrogens roughly doubled VTE risk versus no use, while transdermal estradiol did not significantly increase risk. Women with personal or family history of VTE should discuss this difference with their clinician and consider whether a transdermal formulation with a separate progestogen or levonorgestrel-releasing IUD may be safer.

Breast cancer and monitoring

The bazedoxifene component has an antagonist effect in breast tissue in animal models. However, long-term human breast safety data for CE/BZA is more limited than for CE plus a progestogen, which was studied in the Women's Health Initiative (WHI). The WHI found a statistically significant increase in invasive breast cancer risk with CE plus medroxyprogesterone acetate after 5.6 years of use (hazard ratio 1.26, 95% CI 1.00-1.59). Whether CE/BZA carries a similar, lower, or negligible risk over similar durations is not definitively established in long-duration trials. Annual mammography remains appropriate for all women on Duavee, per standard screening guidelines.

As WomanRx's reviewing clinician Rachel Goldberg, MD, notes: "The most common reason I see women stop progestogen-based HRT is side effects, especially mood changes and breakthrough bleeding. Duavee solves that problem for the right patient, but the cost barrier is real. Every woman I prescribe it to should spend 15 minutes on the Pfizer savings portal and call her insurer before assuming she cannot afford it."

A Step-by-Step Access Checklist for 2026

Use this before your next pharmacy run or prescriber visit.

1. Confirm your uterine status. Duavee is only for women with a uterus. If you have had a hysterectomy, ask your prescriber about estrogen-only alternatives.
2. Confirm you are postmenopausal or have a clear clinical indication. If you are perimenopausal, confirm contraception is in place.
3. Call your insurer. Ask whether Duavee is on formulary, what tier, and whether prior authorization is required.
4. Ask your prescriber's office to submit prior authorization proactively if required, and to document progestogen intolerance or clinical necessity clearly.
5. Check Pfizer's current savings card at pfizer.com. Do not rely on information printed more than 60 days ago.
6. Compare cash prices at three local pharmacies using the Duavee NDC. Sometimes the discount-card price beats the insurance copay.
7. If you are uninsured, ask your prescriber's office to contact Pfizer RxPathways for a patient assistance program application.
8. Re-verify all programs each January, as annual limits reset.

Evidence Gaps Specific to Women

Women were the exclusive trial participants in the SMART program, which is appropriate for a postmenopausal therapy. However, most participants were white and in early postmenopause. Data in Black, Hispanic, and Asian women are limited, as are data beyond two years of continuous use. The WHI taught the field that long-duration HRT risks can diverge from short-duration risks, and CE/BZA has not been studied at WHI-equivalent durations. This matters for your shared decision-making conversation: the evidence base is real but bounded, and it is worth naming that directly with your clinician.